New Diabetes Tech Alert: Abbott and Medtronic Announce Major Partnership

Abbott and Medtronic have entered a global partnership to create a new continuous glucose monitoring (CGM) system, combining Abbott's cutting-edge FreeStyle Libre technology with Medtronic's automated insulin delivery systems and smart insulin pens. This collaboration aims to deliver a holistic diabetes management solution.

The integrated system will automatically adjust insulin levels to help maintain optimal glucose control, benefiting more than 11 million people globally who rely on multiple daily doses of rapid-acting insulin to manage Type 1 and Type 2 diabetes. Medtronic will distribute the CGM sensor that Abbott is designing specifically for compatibility with its devices.

Jared Watkin, executive vice president of Abbott's diabetes care business, said “This partnership pairs two global leaders in glucose sensing technology and insulin delivery. Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic's insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living."

"Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world. We're committed to simplifying diabetes management and making the transition to automated technology much more seamless for those who wish to achieve more with their diabetes care.” said Que Dallara, executive vice president and president, Medtronic Diabetes. 

Abbott's partnership with Medtronic marks another step in its ongoing efforts to enhance and simplify diabetes care, providing patients with more options for effective insulin management. Abbott's Libre single-analyte CGM technology is already accessible and integrated with automated insulin delivery systems from various other companies, reinforcing its commitment to expanding diabetes treatment solutions.